BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3872348)

  • 1. Reduction of fatal complications from combined modality therapy in Hodgkin's disease.
    Mauch PM; Canellos GP; Rosenthal DS; Hellman S
    J Clin Oncol; 1985 Apr; 3(4):501-5. PubMed ID: 3872348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
    Marcus KC; Kalish LA; Coleman CN; Shulman LN; Rosenthal DS; Canellos GP; Mauch PM
    J Clin Oncol; 1994 Dec; 12(12):2567-72. PubMed ID: 7989930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone.
    Mauch P; Goffman T; Rosenthal DS; Canellos GP; Come SE; Hellman S
    J Clin Oncol; 1985 Sep; 3(9):1166-73. PubMed ID: 3839844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
    Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin's disease: experience of the European Organization for Research and Treatment of Cancer.
    Carde P; Hayat M; Cosset JM; Somers R; Burgers JM; Sizoo W; Meerwaldt JH; Hagenbeek A; Monconduit M; van der Schueren E
    NCI Monogr; 1988; (6):303-10. PubMed ID: 3352775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease.
    Andrieu JM; Ifrah N; Payen C; Fermanian J; Coscas Y; Flandrin G
    J Clin Oncol; 1990 Jul; 8(7):1148-54. PubMed ID: 2193118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
    Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The intergroup Hodgkin's disease in children. A study of stages I and II.
    Gehan EA; Sullivan MP; Fuller LM; Johnston J; Kennedy P; Fryer C; Gilchrist GS; Hays DM; Hanson W; Heller R
    Cancer; 1990 Mar; 65(6):1429-37. PubMed ID: 2407336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.
    Klimo P; Connors JM
    J Clin Oncol; 1985 Sep; 3(9):1174-82. PubMed ID: 2411881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
    N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
    Oberlin O; Leverger G; Pacquement H; Raquin MA; Chompret A; Habrand JL; Terrier-Lacombe MJ; Bey P; Bertrand Y; Rubie H
    J Clin Oncol; 1992 Oct; 10(10):1602-8. PubMed ID: 1383434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984.
    Rosenberg SA; Kaplan HS
    Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):5-22. PubMed ID: 3881376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute nonlymphocytic leukemia after radiation and MOPP chemotherapy for Hodgkin's disease.
    Lavey RS
    J Clin Oncol; 1990 Dec; 8(12):2089-90. PubMed ID: 2230901
    [No Abstract]   [Full Text] [Related]  

  • 20. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
    Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.